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Background: The use of secondary data in health care research has 
become a very important issue over the past few years. Data from 
the treatment context are being used for evaluation of medical data 
for external quality assurance, as well as to answer medical ques-
tions in the form of registers and research databases. Additionally, 
the establishment of electronic clinical systems like data warehouses 
provides new opportunities for the secondary use of clinical data. 
Because health data is among the most sensitive information about an 
individual, the data must be safeguarded from disclosure. Depending 
on type of data to be used and the purpose of research, legal require-
ments on secondary use of clinical data vary between countries. The 
US regulations Health Insurance Portability and Accountability Act 
(HIPAA), Health Information Technology for Economic and Clinical 
Health Act (HITECH) and the EU’s Directive 95/46/EC form the legal 
basis for medical research in the United States and the EU and are 
subject to be compared in this project.
Methods: It is of interest to investigate the legal requirements as 
outlined in US and European laws and regulations with the objective 
to identify potential similarities and differences. In order to explore 
the commonalities and differences, a model will be developed that 
contains all aspects that need to be considered prior to providing data 
for secondary uses. The criteria used in this comparison will include 
data privacy how the US and EU regard the secondary use of clinical 
data, which ethical issues are pertinent, and how identifiable and 
de-identified data can be shared.
Results: Some preliminary results include that the US and EU have 
significantly different legal structures for data protection and protect 
personal data differently. While the US approaches privacy by sector 
(i.e. financial and health care separately), the EU takes a more com-
prehensive general approach to privacy. Each European member state 
has its own data protection regulations that must meet the Directives 
requirements. This is accomplished by implementing Directive 95/46 
in their legal structure. In the United States, data protection is frag-
mented into different regulations and acts. While the EU requires 
unambiguous consent from the data subject prior to the collection, 
processing and use of data, HIPAA, the US healthcare privacy law, 
allows organizations to share data for research purposes without 
individual authorization. Both US and European data protection laws 
require that organizations de-identify data prior to disseminating 
it. This implicates that both the United States and the EU assume 
that anonymization protects privacy, which is subject to controversy.
Discussion: The current cursory review has shown a few differences; 
however, a much deeper analysis will be conducted. Indications show a 
much more comprehensive exploration should be conducted since the 
laws and regulations on data protection in the EU and United States are 
immense. Based on the current literature review, little past research has 
compared these complex regulations to this extent before. A comprehen-
sive review offers the potential to improve and facilitate joint research 
projects on health care issues between the EU and the United States.
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Background: From an ethical perspective, clinical research involv-
ing humans is only acceptable if it involves the potential for benefit. 
Various characteristics can be applied to differentiate research benefit. 
Often benefit is categorized in direct or indirect benefit, whereby indi-
rect benefit might be further differentiated in collective or benefit for 
the society, excluding or including the trial patient in the long term. 
Ethical guidelines, such as the Declaration of Helsinki in its latest 
version, do not precisely favor a particular type of benefit. However, 
to conceptualize clinical research benefits it is relevant to differentiate 
between the potential individual benefit or the social benefit expected 
from the study, either with or without a potential long term beneficial 
option for the individual trial participant.
Objectives: The narrative review was designed to screen related liter-
ature to identify the most occurring benefits which could be afforded 
by clinical research and to further detail the beneficial outcomes in 
order to learn about the characteristics values specifying individual 
and social benefits.
Methods: Literature on research benefit was identified by search-
ing PubMed database using several combinations of keywords like 
“benefit” and “clinical research” or “direct benefit” and “clinical 
research.” The search was limited to articles published in English 
language. Likewise, a google search with the same combinations 
of keywords was done. Additionally, the reference lists of instantly 
promising articles were screened for further thematically adapted 
articles.
Results: Based on the reviewed literature it can be stated that the 
principle of benefit from drug development is routinely divided into 
two main classes, namely individual benefits for the patients on one 
hand and into collective benefits for the society.1 Thirty-four of an 
overall 39 articles and publications by governmental medical insti-
tutes focused on the personal benefit of the patients. In this group 
the leading benefits were an increased quality of life (42.2%), access 
to health care and drugs (29.4%), up-to-date care (29.4%), feeling 
of altruism and helping future patients (17.6%), payments received 
(17.6%), and improvement of survival rate (14.7%). The collective 
benefit was discussed in 18 of the articles. The main benefits in this 
area were the general knowledge gain (72.2%), subsequent availabil-
ity of new treatments and drugs (27.8%), better access to medicines 
(11.1%), sustainability of health care (11.1%), and improvement of 
health care (11.1%).
Conclusions: Individual patient benefit from drug development 
appears to be more frequent than benefits concerning the society 
in general. Though a scientific approach is population based and 
consequently closer to the social benefit category, the data might not 
only be purely statistically evaluated. Each individual patient has the 
right to look and hope for a personal benefit from participating in a 
clinical trial without putting a feeling of pure altruism on top prior-
ity.2 From an ethical point of view each benefit achieved for individual 
patients as part of a clinical trial testing new treatments, drugs or 
medicinal products, might be seen as social benefit as well, and even 
more in case the tested drug or device will be made available for all 
patients of the country, where the clinical trial was conducted, after 
its’ market approval.3
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